Monday, February 20, 2017 5:00:10 PM
Theralase Extends Research Agreement with University Health Network
April 28, 2016, Theralase Technologies Inc., a leading biotech company focused on commercialization of medical devices to eliminate pain and development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has extended its Sponsored Research Agreement (“SRA”) with University Health Network (“UHN”), one of the top 5 cancer research institutes in the world.
Under the terms of the SRA, Theralase and UHN will work together to evaluate Theralase’s patented and patent pending platform of novel Ruthenium (“Ru”) and Osmium (“Os”) based PDCs for new cancer indications, including: lung, melanoma and brain cancer.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM